Overview

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

Status:
Not yet recruiting

Trial end date:
2023-01-31

Target enrollment:

Participant gender:

Summary

To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer. To assess the relationship of tumor size, histologic subtype and location of lesion and how it affects lesion conspicuity and sensitivity in MBI detected cancers.

Phase:

Early Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Technetium Tc 99m Sestamibi